Characteristics of Patients with Type-1 or Type-2 Diabetes Receiving Insulin Glargine U300: An Analysis of 7268 Patients Based on the DPV and DIVE Registries-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Characteristics of Patients with Type-1 or Type-2 Diabetes Receiving Insulin Glargine U300: An Analysis of 7268 Patients Based on the DPV and DIVE Registries

Published:2019-05-22 Issue:7 Volume:36 Page:1628-1641
ISSN:0741-238X
Container-title:Advances in Therapy
language:en
Short-container-title:Adv Ther

Author:

van Mark Gesine,Lanzinger Stefanie,Sziegoleit Stefan,Putz Franz Josef,Durmaz Mesut,Borscheller Michaela,Danne Thomas,Seufert Jochen,Holl Reinhard W.,Bramlage Peter^ORCID

Funder

DZD - German Centre for Diabetes Research

EFSD - European Foundation for the Study of Diabetes

Deutsche Diabetes Gesellschaft

Sanofi

AstraZeneca

Bayer

Abbott Laboratories

diabetesDE

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),General Medicine

Link

http://link.springer.com/content/pdf/10.1007/s12325-019-00983-w.pdf

Reference36 articles.

1. Sutton G, et al. U300, a novel long-acting insulin formulation. Expert Opin Biol Ther. 2014;14:1849–60.

2. Vargas-Uricoechea H. Efficacy and safety of insulin glargine 300 U/mL versus 100 U/mL in diabetes mellitus: a comprehensive review of the literature. J Diabetes Res. 2018;2018:2052101.

3. Bohn B, et al. Welche Patienten aus der Routinebetreuung verwenden das neue Insulin-Analogon Glargin U300 im Vergleich zu Patienten mit Glargin U100? Eine multizentrische Analyse von 14.123 Patienten mit Insulin Glargin aus den Diabetesregistern DPV und DIVE. Wien Med Wochenschr. 2017;168:415–22.

4. Ritzel R, et al. Patient-level meta-analysis of the EDITION 1, 2 and 3 studies: glycaemic control and hypoglycaemia with new insulin glargine 300 U/ml versus glargine 100 U/ml in people with type 2 diabetes. Diabetes Obes Metab. 2015;17:859–67.

5. Home PD, et al. New insulin glargine 300 units/mL versus glargine 100 units/mL in people with type 1 diabetes: a randomized, phase 3a, open-label clinical trial (EDITION 4). Diabetes Care. 2015;38:2217–25.

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Use of Second-Generation Basal Insulin Gla-300 in Special Populations: A Narrative Mini-Review;Current Diabetes Reviews;2023-11

2. 100 Jahre Insulin: Wie hat sich die Insulintherapie bei Erwachsenen zwischen 2000 und 2021 verändert?;Diabetologie und Stoffwechsel;2023-04-21

3. Estimates of insulin needs and dispensation given wastage, alternative glycemic targets, and non-insulin therapies in US populations with type 2 diabetes mellitus: A microsimulation study;Journal of Diabetes and its Complications;2021-04

4. Insulin doses requirements in patients with type 1 diabetes using glargine U300 or degludec in routine clinical practice;Journal of Investigative Medicine;2021-03-26

5. Concentrated Insulins: Clinical Update of Therapeutic Options;Endocrine Practice;2020-06

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3